Published in:

01-11-2020 | Rituximab | Correction

Correction to: Efficacy and safety results from a randomized double-blind study comparing proposed biosimilar ABP 798 with rituximab reference product in subjects with moderate-to-severe rheumatoid arthritis

Authors: Gerd Burmester, Edit Drescher, Pawel Hrycaj, David Chien, Zhiying Pan, Stanley Cohen

Published in: Clinical Rheumatology | Issue 11/2020